Dehydroepiandrosterone for myotonic dystrophy type 1

Neurology

Volumn 71, Issue 6, 2008, Pages 407-412

  Penisson Besnier I ^a   Devillers, M ^a   Porcher, R ^a   Orlikowski, D ^a   Doppler, V ^a   Desnuelle, C ^a   Ferrer, X ^a   Bes, M C A ^a   Bouhour, F ^a   Tranchant, C ^a   Lagrange, E ^a   Vershueren, A ^a   Uzenot, D ^a   Cintas, P ^a   Sole G ^a   Hogrel, J Y ^a   Laforet P ^a   Vial, C ^a   Vila, A L ^a   Sacconi, S ^a   Pouget, J ^a   Eymard, B ^a   Chevret, S ^a   Annane, D ^a   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; CAPSULE ENDOSCOPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVENING DOSAGE; FEMALE; FRANCE; FUNCTION TEST; HEART ATRIUM FLUTTER; HEART FUNCTION; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE FUNCTION; MUSCLE STRENGTH; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOMA; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; BIOASSAY; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SKELETAL MUSCLE;

ADULT; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOTONIC DYSTROPHY; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 49049095956     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324257.35759.40     Document Type: Article

References (17)

1. Harper PS, van Engelen BGM, Eymard B, Wilcox D, eds. Myotonic Dystrophy: Present Management, Future Therapy. Oxford: Oxford University Press, 2004.
2. Mankodi A, Urbinati CR, Yuan QP, et al. Muscle blind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001;10:2165-2170.
3. Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-348.
4. Carter JN, Steinbeck KS. Reduced adrenal androgens in patients with myotonic dystrophy. J Clin Endocrinol Metab 1985;60:611-614.
5. Tsuji K, Furutama D, Tagami M, Ohsawa N. Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myo-tonic dystrophy. Life Sci 1999;65:17-26.
6. Sugino M, Ohsawa N, Ito T, et al. A pilot study of dehy- droepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-589.
7. Thornton C, Mankodi A, Barbieri C, et al. Pilot trial of oral dehydroepiandrosterone sulfate (DHEAS) in myo-tonic dystrophy (DM). Neurology 2001;56 (suppl 3): A80-A81.
8. Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001;56:336-340.
9. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
10. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306:1437-1440.
11. Mendell JR, Florence J. Manual muscle testing. Muscle Nerve 1990;S16-S20.
12. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for lateral amyotrophic sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
13. Mathieu J, Boivin H, Richards CL. Quantitative motor assessment in myotonic dystrophy. Can J Neurol Sci 2003; 30:129-136.
14. Dhatariya KK, Nair KS. Dehydroepiandrosterone: is there a role for replacement? Mayo Clin Proc 2003;78:1257-1273.
15. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-1659.
16. Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003;163:720-727.
17. Griggs RC, Pandya S, Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989;39:219-222.